Atossa is developing afimoxifene topical gel (AfTG), intended to provide transdermal selective estrogen receptor modulation (SERM) to the breast area while reducing the adverse events associated with oral SERM drugs. Atossa is also advancing its proprietary intraductal microcatheter (IDMC) intended to selectively introduce drug to breast ducts, potentially improving drug targeting for chemotherapy. It plans to combine its IDMC with established cancer drug fulvestrant and start a Phase II study in H116. Our rNPV-derived equity valuation is $14.2m.
